Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 10, Pages 2171
Publisher
MDPI AG
Online
2017-10-18
DOI
10.3390/ijms18102171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reverse the Resistance to PARP Inhibitors
- (2017) Yevgeniy Kim et al. International Journal of Biological Sciences
- The role of exosomes and miRNAs in drug-resistance of cancer cells
- (2017) Duc-Hiep Bach et al. INTERNATIONAL JOURNAL OF CANCER
- The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
- (2017) Shunfei Yan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Exosomes: From Garbage Bins to Promising Therapeutic Targets
- (2017) Mohammed H. Rashed et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
- (2017) Xinxin Zhu et al. Journal of Gynecologic Oncology
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer
- (2017) Xiaoduan Li et al. Molecular Cancer
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
- (2017) Hong Xu et al. Nature Communications
- Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress
- (2017) Parag P. Shah et al. Oncotarget
- Exosomes as mediators of platinum resistance in ovarian cancer
- (2017) Jennifer Crow et al. Oncotarget
- Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells
- (2017) Jinheng Wang et al. Frontiers in Pharmacology
- The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy
- (2017) Raafat El-Awady et al. Frontiers in Pharmacology
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
- (2017) Tarra Evans et al. Therapeutic Advances in Medical Oncology
- Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
- (2017) Stefanie Aust et al. Scientific Reports
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer
- (2016) J. Krzystyniak et al. ANNALS OF ONCOLOGY
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
- (2016) Gwo Yaw Ho et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
- (2016) Yifan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
- (2016) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models
- (2016) Mohamad Hadla et al. Nanomedicine
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1
- (2016) Di-di Wu et al. TUMOR BIOLOGY
- The Current Status of PARP Inhibitors in Ovarian Cancer
- (2016) Jennifer McLachlan et al. TUMORI
- Recent perspectives of epithelial ovarian carcinoma
- (2016) Xiao-Ying Zhang et al. Oncology Letters
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Choline Metabolism Alteration: A Focus on Ovarian Cancer
- (2016) Marina Bagnoli et al. Frontiers in Oncology
- The Current Status of PARP Inhibitors in Ovarian Cancer
- (2016) Jennifer McLachlan et al. TUMORI JOURNAL
- A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
- (2016) Takuya Sakamoto et al. PLoS One
- The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy
- (2015) Simone J. Woods et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells
- (2015) Ming-Jer Young et al. CARCINOGENESIS
- Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
- (2015) Dana M. Roque et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene
- (2015) Michael M. Gottesman et al. JNCI-Journal of the National Cancer Institute
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity
- (2015) Anne Margriet Heijink et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells
- (2015) Biao Wang et al. TUMOR BIOLOGY
- Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
- (2015) Flora Zagouri et al. OncoTargets and Therapy
- MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
- (2015) Xiaoqian Yang et al. Scientific Reports
- The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene
- (2015) Michael M. Gottesman et al. JNCI-Journal of the National Cancer Institute
- DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response
- (2015) Laureen Colis et al. Oncotarget
- Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
- (2015) Zachary C. Dobbin et al. Oncotarget
- Angiopoietins Promote Ovarian Cancer Progression by Establishing a Procancer Microenvironment
- (2014) Melissa K. Brunckhorst et al. AMERICAN JOURNAL OF PATHOLOGY
- Targeting the nucleolus for cancer intervention
- (2014) Jaclyn E. Quin et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
- (2014) Sunila Pradeep et al. CANCER CELL
- A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity
- (2014) Karita Peltonen et al. CANCER CELL
- Endothelin A Receptor/ -Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy
- (2014) L. Rosano et al. CANCER RESEARCH
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer
- (2014) Ellen L. Hedditch et al. JNCI-Journal of the National Cancer Institute
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress
- (2014) K. Peltonen et al. MOLECULAR CANCER THERAPEUTICS
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- Targeting RNA polymerase I to treat MYC-driven cancer
- (2014) G Poortinga et al. ONCOGENE
- Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
- (2014) Q H Miow et al. ONCOGENE
- Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
- (2014) Xiaoqian Yang et al. PHARMACEUTICAL RESEARCH
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Nanodrug delivery in reversing multidrug resistance in cancer cells
- (2014) Mayur Yergeri et al. Frontiers in Pharmacology
- Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors
- (2013) Su Chul Jang et al. ACS Nano
- The role of the fallopian tube in the origin of ovarian cancer
- (2013) Britt K. Erickson et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- The Cell’s Nucleolus: an Emerging Target for Chemotherapeutic Intervention
- (2013) Amanda J. Pickard et al. ChemMedChem
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
- (2013) Ziyad Binkhathlan et al. CURRENT CANCER DRUG TARGETS
- Identification of miRNA modulators to PARP inhibitor response
- (2013) Sari Neijenhuis et al. DNA REPAIR
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
- (2013) Sharon E. Johnatty et al. GYNECOLOGIC ONCOLOGY
- Notch3 induces epithelial–mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells
- (2013) Nidhi Gupta et al. GYNECOLOGIC ONCOLOGY
- Exosomes as Intercellular Signaling Organelles Involved in Health and Disease: Basic Science and Clinical Applications
- (2013) Chiara Corrado et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
- (2013) Khalid Abubaker et al. Molecular Cancer
- Topoisomerase IIα promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation
- (2013) Swagat Ray et al. Nature Communications
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Mechanisms and insights into drug resistance in cancer
- (2013) Hiba Zahreddine et al. Frontiers in Pharmacology
- The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
- (2013) Raquel E. Reinbolt et al. Frontiers in Oncology
- The Tumor Microenvironment and Strategies to Improve Drug Distribution
- (2013) Jasdeep K. Saggar et al. Frontiers in Oncology
- EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
- (2012) Alexandria M Haslehurst et al. BMC CANCER
- Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis
- (2012) A. Bagnato et al. Current Oncology
- Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
- (2012) Sergio Marchini et al. EUROPEAN JOURNAL OF CANCER
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
- (2012) Mustapha Haddach et al. ACS Medicinal Chemistry Letters
- Epithelial–Mesenchymal Transition in Ovarian Carcinoma
- (2012) Ben Davidson et al. Frontiers in Oncology
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells
- (2011) L. Rosano et al. CLINICAL CANCER RESEARCH
- Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
- (2011) S. Shukla et al. CURRENT DRUG TARGETS
- Epothilones in the treatment of ovarian cancer
- (2011) Ivan Diaz-Padilla et al. Future Oncology
- RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer
- (2011) Prakash Vishnu et al. GYNECOLOGIC ONCOLOGY
- Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance
- (2011) Yunfeng Fu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile
- (2011) Ardian Latifi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Evolution of platinum resistance in high-grade serous ovarian cancer
- (2011) Susanna L Cooke et al. LANCET ONCOLOGY
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- Targeting Multidrug Resistance with Small Molecules for Cancer Therapy
- (2010) Yan Xia et al. Biomolecules & Therapeutics
- 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
- (2010) N. Issaeva et al. CANCER RESEARCH
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
- (2010) Y.-j. Mi et al. CANCER RESEARCH
- The Nucleolus under Stress
- (2010) Séverine Boulon et al. MOLECULAR CELL
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- What the nucleolus says to a tumour pathologist
- (2009) Massimo Derenzini et al. HISTOPATHOLOGY
- Drug Resistance Caused by Reversion Mutation
- (2008) A. Ashworth CANCER RESEARCH
- ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy
- (2008) S. E. Johnatty et al. CLINICAL CANCER RESEARCH
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exosome Function: From Tumor Immunology to Pathogen Biology
- (2008) Jeffrey S. Schorey et al. TRAFFIC
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now